PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
28.86%
Similar G&A growth to CRVO's 37.03%. Walter Schloss would investigate industry cost structures.
No Data
No Data available this quarter, please select a different quarter.
-40.21%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
6.04%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
6.04%
Total costs growth less than half of CRVO's 15.98%. David Dodd would verify sustainability.
-100.00%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-40.21%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-66.22%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-6.04%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-333.64%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-65.74%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-65.74%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-47.67%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-53.82%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
12.14%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
7.50%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.